Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 9/2010

01-11-2010 | Original Article

Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction

Authors: Shigehiko Katoh, Tetsuro Shishido, Daisuke Kutsuzawa, Takanori Arimoto, Shunsuke Netsu, Akira Funayama, Mitsunori Ishino, Takeshi Niizeki, Satoshi Nishiyama, Hiroki Takahashi, Takehiko Miyashita, Takuya Miyamoto, Joji Nitobe, Tetsu Watanabe, Isao Kubota

Published in: Annals of Nuclear Medicine | Issue 9/2010

Login to get access

Abstract

Objective

Iodine-123-metaiodobenzylguanidine (123I-MIBG) has been used to assess the function of the cardiac sympathetic nervous system in patients with chronic heart failure (HF). The usefulness of 123I-MIBG imaging for evaluating patients with heart failure with preserved ejection fraction (HFPEF) has not been established.

Methods

We performed 123I-MIBG scintigraphy and echocardiography and measured the plasma brain natriuretic peptide (BNP) levels of 117 consecutive HF patients (64 men, mean age 66 ± 14 years) with a left ventricular ejection fraction (LVEF) of ≥50% who were admitted to our hospital. Patients were divided into 2 groups according to the New York Heart Association (NYHA) functional class.

Results

The 123I-MIBG delayed heart-to-mediastinum (H/M) ratio was significantly lower, and the washout rate (WR) was higher in patients with HFPEF with advanced NYHA functional class (NYHA functional class I and II vs. III: 1.90 ± 0.34 vs. 1.49 ± 0.32, p < 0.0001; 25.9 ± 13.4 vs. 46.9 ± 16.3%, p < 0.0001, respectively). On the other hand, the 123I-MIBG WR was not correlated with LVEF and had a weak correlation with plasma BNP levels (R = 0.207, p = 0.0346). Moreover, patients with a high 123I-MIBG WR showed a poor clinical outcome (p = 0.0033).

Conclusions

123I-MIBG imaging provides independent prognostic information in patients with HFPEF.
Literature
1.
Eisenhofer G, Friberg P, Rundqvist B, Quyyumi AA, Lambert G, Kaye DM, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93:1667–76.PubMed
2.
Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation. 1997;95:169–75.PubMed
3.
Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992;20:248–54.CrossRefPubMed
4.
Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–23.CrossRefPubMed
5.
Heilbrunn SM, Shah P, Bristow MR, Valantine HA, Ginsburg R, Fowler MB. Increased beta-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation. 1989;79:483–90.PubMed
6.
Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579–90.CrossRefPubMed
7.
Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol. 1995;26:1594–9.CrossRefPubMed
8.
Agostini D, Carrio I, Verberne HJ. How to use myocardial 123I-MIBG scintigraphy in chronic heart failure. Eur J Nucl Med Mol Imaging. 2009;36:555–9.CrossRefPubMed
9.
Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202.CrossRefPubMed
10.
Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999;33:1948–55.CrossRefPubMed
11.
Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81.CrossRefPubMed
12.
Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction. Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). Circ J. 2009;73:1893–900.CrossRefPubMed
13.
Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation. 2006;114:2138–47.CrossRefPubMed
14.
Kitahara T, Shishido T, Suzuki S, Katoh S, Sasaki T, Ishino M, et al. Serum midkine as a predictor of cardiac events in patients with chronic heart failure. J Card Fail. 2010;16:308–13.CrossRefPubMed
15.
Takeishi Y, Atsumi H, Fujiwara S, Takahashi K, Tomoike H. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med. 1997;38:1085–9.PubMed
16.
Sasaki T, Takeishi Y, Suzuki S, Niizeki T, Kitahara T, Katoh S, et al. High serum level of neopterin is a risk factor of patients with heart failure. Int J Cardiol. 2010 [Epub ahead of print].
17.
Estorch M, Carrio I, Mena E, Flotats A, Camacho V, Fuertes J, et al. Challenging the neuronal MIBG uptake by pharmacological intervention: effect of a single dose of oral amitriptyline on regional cardiac MIBG uptake. Eur J Nucl Med Mol Imaging. 2004;31:1575–80.CrossRefPubMed
18.
Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.CrossRefPubMed
19.
Grassi G, Seravalle G, Quarti-Trevano F, Dell’Oro R, Bolla G, Mancia G. Effects of hypertension and obesity on the sympathetic activation of heart failure patients. Hypertension. 2003;42:873–7.CrossRefPubMed
20.
Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, et al. Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA. 2002;288:2144–50.CrossRefPubMed
21.
Powers FM, Pifarre R, Thomas JX Jr. Ventricular dysfunction in norepinephrine-induced cardiomyopathy. Circ Shock. 1994;43:122–9.PubMed
22.
Deten A, Shibata J, Scholz D, Briest W, Wagner KF, Wenger RH, et al. Norepinephrine-induced acute heart failure in transgenic mice overexpressing erythropoietin. Cardiovasc Res. 2004;61:105–14.CrossRefPubMed
23.
Lee JC, Downing SE. Ventricular function in norepinephrine-induced cardiomyopathic rabbits. Am J Physiol. 1982;242:H191–6.PubMed
24.
Lorell BH, Grossman W. Cardiac hypertrophy: the consequences for diastole. J Am Coll Cardiol. 1987;9:1189–93.CrossRefPubMed
25.
Levi R, Silver RB, Mackins CJ, Seyedi N, Koyama M. Activation of a renin-angiotensin system in ischemic cardiac sympathetic nerve endings and its association with norepinephrine release. Int Immunopharmacol. 2002;2:1965–73.CrossRefPubMed
26.
Sugiura M, Yamamoto K, Takeda Y, Dohmori T, Ogata M, Kondo H, et al. The relationship between variables of 123-I-metaiodobenzylguanidine cardiac imaging and clinical status of the patients with diastolic heart failure. Int J Cardiol. 2006;113:223–8.CrossRefPubMed
27.
Isobe S, Izawa H, Iwase M, Nanasato M, Nonokawa M, Ando A, et al. Cardiac 123I-MIBG reflects left ventricular functional reserve in patients with nonobstructive hypertrophic cardiomyopathy. J Nucl Med. 2005;46:909–16.PubMed
28.
Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effects of candesartan on cardiac sympathetic nerve activity in patients with congestive heart failure and preserved left ventricular ejection fraction. J Am Coll Cardiol. 2005;45:661–7.CrossRefPubMed
29.
Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, et al. Usefulness of N-terminal pro-brain natriuretic peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Am J Cardiol. 2008;102:733–7.CrossRefPubMed
30.
Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation. 2004;109:3176–81.CrossRefPubMed
31.
Forfia PR, Watkins SP, Rame JE, Stewart KJ, Shapiro EP. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol. 2005;45:1667–71.CrossRefPubMed
32.
Yamamoto K, Nishimura RA, Chaliki HP, Appleton CP, Holmes DR Jr, Redfield MM. Determination of left ventricular filling pressure by Doppler echocardiography in patients with coronary artery disease: critical role of left ventricular systolic function. J Am Coll Cardiol. 1997;30:1819–26.CrossRefPubMed
Metadata
Title
Iodine-123-metaiodobenzylguanidine imaging can predict future cardiac events in heart failure patients with preserved ejection fraction
Authors
Shigehiko Katoh
Tetsuro Shishido
Daisuke Kutsuzawa
Takanori Arimoto
Shunsuke Netsu
Akira Funayama
Mitsunori Ishino
Takeshi Niizeki
Satoshi Nishiyama
Hiroki Takahashi
Takehiko Miyashita
Takuya Miyamoto
Joji Nitobe
Tetsu Watanabe
Isao Kubota
Publication date
01-11-2010
Publisher
Springer Japan
Published in
Annals of Nuclear Medicine / Issue 9/2010
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-010-0409-3

Other articles of this Issue 9/2010

Annals of Nuclear Medicine 9/2010 Go to the issue

Short Communication

Relative renal function with MAG-3 and DMSA in children with unilateral hydronephrosis

Original Article

Imaging of a rat osteoarthritis model using 18F-fluoride positron emission tomography

Original Article

A practical method of determining cross-calibration factors of PET scanners by moving a point-like 22Na radioactive source

Review Article

Nuclear neuroimaging in acute and subacute ischemic stroke

Original Article

Positron emission tomography inter-scanner differences in dopamine D2 receptor binding measured with [11C]FLB457

Case Report

F-18 FDG PET/CT in relapsing polychondritis